Ontario, Calif., January 16, 2023 — Kiwa Bio-Tech Products Group Corporation (“Kiwa” or the “Company”) (PINK: KWBT). On January 16, 2023, The board of directors of Kiwa Bio-Tech Products Group Corporation (hereinafter referred to as KIWA or the company) held a meeting. Upon the nomination of Ms. Ziqi Wang, the chairman, and the consent of all directors, it was decided to hire Mr. Zuyan Ye as the president of the company for a period of two years.
Mr. Ye once served as the co-founder and CEO of China Digital Technology Enterprise Chaixiang Group, and successfully led Chaixiang Group to achieve good results in the digital technology industry in the region.
After being employed as the president of Kiwa, Mr. Ye will be responsible for the management and operation of the company’s blockchain, metauniverse and other new businesses. Ms. Ziqi Wang, the chairman, said that after Mr. Ye joined the company and launched the new business plan, it indicated that the company would gradually adjust its core business.
Forward-Looking Statements
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company’s reports filed with the U.S. Securities and Exchange Commission. The forward-looking information provided herein represents the Company’s estimates as of the date of the press release, and subsequent events and developments may cause the Company’s estimates to change. The Company’s actual results may differ materially from those anticipated in the forward-looking statements depending on a number of risk factors including, but not limited to, the following: general economic, business and environment conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, the execution of its ten-year growth plan, the foreign exchange risk amid the unexpected announcements by the PRC government and various other factors beyond the Company’s control. Kiwa Bio-Tech Products Group Corp. specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company’s estimates of its future financial performance as of any date subsequent to the date of this press release.
For investor and media inquiries, please contact:
Email: myli@kiwabiotech.com
